Evidence map›Paper›PMID 39384331›Full record

ArticleBMJ global health2024

Understanding the barriers and facilitators related to never treatment during mass drug administration among mobile and migrant populations in Mali: a qualitative exploratory study.

Moussa Sangare, Abdoul Fatao Diabate, Yaya Ibrahim Coulibaly, Diadje Tanapo, Sekou Oumarou Thera, Housseini Dolo, Ilo Dicko, Oumar Coulibaly, Binta Sall, Fatoumata Traore and 4 more

Registry-linked trialAbstract read
In one paragraph

Article in BMJ global health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07707817 (A Community Mapping and Participatory Research Protocol for Expanding Access to Preventive Chemotherapy Among Mobile and Migrant Populations Through Social and Occupational Networks in Nigeria), which is not on this map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07707817 narecruitingnot on this mapstarted 2026, after this paper: background citation

A Community Mapping and Participatory Research Protocol for Expanding Access to Preventive Chemotherapy Among Mobile and Migrant Populations Through Social and Occupational Networks in Nigeria: MISSION Nigeria

TypeinterventionalSponsorUwemedimo Friday EkpoRan2026 to 2027Enrolled5,760ConditionsOnchocerciasis (River Blindness), Schistosomiasis, Soil Transmitted Helminth (STH) Infections, Lymphatic FilariasisArmsModified Mass Administration of Medicines Strategy, Albendazole 400 mg, Praziquantel 40 mg/kg, Ivermectin, Ivermectin + albendazole
3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Moussa SangareInternational Center of Excellence in Research in Mali, University of Sciences, Techniques, and Technologies of Bamako, Bamako, Mali mbsangare@icermali.org msang030@uottawa.ca.ORCID http://orcid.org/0000-0001-9582-4093
Abdoul Fatao DiabateInternational Center of Excellence in Research in Mali, University of Sciences, Techniques, and Technologies of Bamako, Bamako, Mali.
Yaya Ibrahim CoulibalyInternational Center of Excellence in Research in Mali, University of Sciences, Techniques, and Technologies of Bamako, Bamako, Mali.
Diadje TanapoInternational Center of Excellence in Research in Mali, University of Sciences, Techniques, and Technologies of Bamako, Bamako, Mali.
Sekou Oumarou TheraInternational Center of Excellence in Research in Mali, University of Sciences, Techniques, and Technologies of Bamako, Bamako, Mali.
Housseini DoloInternational Center of Excellence in Research in Mali, University of Sciences, Techniques, and Technologies of Bamako, Bamako, Mali.
Ilo DickoInternational Center of Excellence in Research in Mali, University of Sciences, Techniques, and Technologies of Bamako, Bamako, Mali.
Oumar CoulibalyInternational Center of Excellence in Research in Mali, University of Sciences, Techniques, and Technologies of Bamako, Bamako, Mali.
Binta SallInternational Center of Excellence in Research in Mali, University of Sciences, Techniques, and Technologies of Bamako, Bamako, Mali.
Fatoumata TraoreInternational Center of Excellence in Research in Mali, University of Sciences, Techniques, and Technologies of Bamako, Bamako, Mali.
Seydou DoumbiaInternational Center of Excellence in Research in Mali, University of Sciences, Techniques, and Technologies of Bamako, Bamako, Mali.
Manisha A KulkarniSchool of Epidemiology and Public Heath, University of Ottawa Faculty of Medicine, Ottawa, Ontario, Canada.
Thomas B NutmanLaboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA.
Alison KrentelBruyère Research Institute, Ottawa, Ontario, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionFive of the neglected tropical diseases use a strategy of preventative chemotherapy distributed via mass drug administration (MDA) for all eligible people living in endemic areas. To be successful, high coverage must be sustained over multiple rounds. Therefore, it will be difficult to reach elimination as a public health problem using MDA if there remain clusters of people who have never been treated. The study aims to explore the reasons why people with high mobility report being never treated during MDA and to provide evidence to support the development of standardised questions for data collection using qualitative research tools.

methodsWe conducted an exploratory study using qualitative methods among displaced people, nomads/transhumants and economic migrants who self-reported that they had never been treated during MDA in the health districts of Tominian and Kalabancoro in Mali. Data were collected through in-depth individual interviews and focus group discussions. Nvivo V.14 software was used for data management and analysis.

resultsThe main reasons reported for never treatment included: geographical mobility, lack of awareness/information, negative rumours, fear of side effects, conflict and insecurity and logistical difficulties faced in reaching these populations. Proposed solutions included involving communities in the MDA, increasing awareness and information campaigns, effectively managing side effects, and designing and implementing flexible and effective interventions.

conclusionThis study highlights that there are people with high mobility who may never have been treated during any round of MDA. The reasons for never treatment highlight the challenges faced when reaching particular groups during MDA activities/interventions. Suggested remedies will require programmes to implement more flexible and tailored interventions. Customised approaches based on the context are essential to guarantee fair access to preventive chemotherapy. Effective interventions must consider the supply and demand side in crafting interventions. This research adds to the evidence base to understand never treatment, particularly among highly mobile population groups and in schistosomiasis elimination programmes.

Indexed as

Mass Drug AdministrationQualitative ResearchTransients and MigrantsAdultFemaleFocus GroupsHealth Knowledge, Attitudes, PracticeHealth Services AccessibilityHumansMaleMaliMiddle AgedNeglected DiseasesSchistosomiasisControl strategiesInfections, diseases, disorders, injuriesPublic HealthSystematic review

Identifiers

PMID39384331
PMCPMC11474861

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.